Key result
Intravenous milrinone showed a bidirectional effect, tending to increase cardiovascular hospital days in ischemic HF but decrease them in nonischemic HF.
Why the study?
Heart failure etiology has prognostic and therapeutic implications, but its relationship to response to inotropic therapy is unknown.
Does intravenous milrinone improve outcomes in patients with decompensated heart failure based on ischemic versus nonischemic etiology?
RCT (n=949)
Does intravenous milrinone improve outcomes in patients with decompensated heart failure based on ischemic versus nonischemic etiology?
In decompensated heart failure, intravenous milrinone may be harmful in patients with ischemic etiology but potentially beneficial in those with nonischemic etiology.
Answers are grounded in this paper and cite their sources.
Etiology may modify milrinone response in decompensated HF; challenges uniform inotrope use and leaves open etiology-specific trials.
OBJECTIVES: The goal of this study was to assess the interaction between heart failure (HF) etiology and response to milrinone in decompensated HF. BACKGROUND: Etiology has prognostic and therapeutic implications in HF, but its relationship to response to inotropic therapy is unknown. METHODS: The Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study randomized 949 patients with systolic dysfunction and decompensated HF to receive 48 to 72 h of intravenous milrinone or placebo. The primary end point was days hospitalized from cardiovascular causes within 60 days. In a post-hoc analysis, we evaluated the interaction between response to milrinone and etiology of HF. RESULTS: The primary end point was 13.0 days for ischemic patients and 11.7 days for nonischemic patients (p = 0.2). Sixty-day mortality was 11.6% for the ischemic group and 7.5% for the nonischemic group (p = 0.03). After adjustment for baseline differences, there was a significant interaction between etiology and the effect of milrinone. Milrinone-treated patients with ischemic etiology tended to have worse outcomes than those treated with placebo in terms of the primary end point (13.6 days for milrinone vs. 12.4 days for placebo, p = 0.055 for interaction) and the composite of death or rehospitalization (42% vs. 36% for placebo, p = 0.01 for interaction). In contrast, outcomes in nonischemic patients treated with milrinone tended to be improved in terms of the primary end point (10.9 vs. 12.6 days placebo) and the composite of death or rehospitalization (28% vs. 35% placebo). CONCLUSIONS: Milrinone may have a bidirectional effect based on etiology in decompensated HF. Milrinone may be deleterious in ischemic HF, but neutral to beneficial in nonischemic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Felker et al. (2003) conducted an RCT in Decompensated heart failure (n=949). Milrinone vs. Placebo was evaluated on Days hospitalized from cardiovascular causes within 60 days. Intravenous milrinone showed a bidirectional effect, tending to increase cardiovascular hospital days in ischemic HF but decrease them in nonischemic HF.
Synapse has enriched 10 related papers. Consider them for comparative context: